Figitumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade

Introduction

Figitumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R) and is used for research purposes. This biosimilar is designed to mimic the activity of the original Figitumumab antibody, which was developed as a potential cancer therapy. In this article, we will discuss the structure, activity, and potential applications of Figitumumab Biosimilar.

Structure of Figitumumab Biosimilar

Figitumumab Biosimilar is a recombinant humanized monoclonal antibody that is produced in a laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, each with a specific amino acid sequence. The antibody has a molecular weight of approximately 150 kDa.

The heavy chains of Figitumumab Biosimilar consist of four constant regions (Fc) and one variable region (VH), while the light chains have two constant regions (CL) and one variable region (VL). The variable regions are responsible for binding to the IGF1R receptor, while the constant regions determine the antibody’s effector functions.

Activity of Figitumumab Biosimilar

Figitumumab Biosimilar binds to the IGF1R receptor, which is a transmembrane protein found on the surface of cells. This receptor plays a crucial role in cell proliferation, survival, and differentiation. When IGF1R is activated by its ligands, it triggers a signaling cascade that promotes cell growth and survival.

By binding to IGF1R, Figitumumab Biosimilar blocks the activation of the receptor and inhibits the downstream signaling pathway. This leads to a decrease in cell growth and survival, making it a potential anti- cancer agent. Additionally, Figitumumab Biosimilar can also induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to kill cancer cells.

Potential Applications of Figitumumab Biosimilar

Figitumumab Biosimilar has been primarily studied for its potential as a cancer therapy. It has shown promising results in preclinical studies and has been evaluated in clinical trials for various types of cancer, including lung, breast, and prostate cancer. However, due to the limited efficacy and safety concerns, the development of the original Figitumumab antibody was discontinued.

The biosimilar version of Figitumumab can be used in research to study the role of IGF1R in cancer and other diseases. It can also be used as a tool to assess the efficacy and safety of potential IGF1R-targeted therapies. Furthermore, Figitumumab Biosimilar can also be used as a reference standard for quality control and bioassays in the development of other biosimilar antibodies.

Conclusion

In summary, Figitumumab Biosimilar is a recombinant humanized monoclonal antibody that targets the IGF1R receptor. It has a similar structure and activity to the original Figitumumab antibody and has shown potential in cancer therapy. However, further research is needed to fully understand its efficacy and safety. Figitumumab Biosimilar also has potential applications in research and as a reference standard for biosimilar development.